| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.4 | 0.7 |
| Net income | -41.2 | -33.7 |
| EPS (diluted, $ a share) | $-0.75 | $-0.63 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -42.2% |
|---|
10-Q filed with the SEC, NASDAQ: UPB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Upstream Bio, Inc.: key numbers
- Share price
- $2.15Close, Nov 16
- Market cap
- $118M
- Shares outstanding
- 54.81MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Upstream Bio, Inc.
All →Upstream Bio Financial Results
Upstream Bio reported third quarter 2026 financial results, ending the period with $207.4 million in cash and short-term investments. The company is preparing to initiate Phase 3 trials for its lead candidate verekitug in severe asthma and CRSwNP in the first quarter of 2027. Research and development expenses increased to $36.6 million as the company advances its clinical programs and expands its personnel.
- Term
- Q3 2026
“Our team is focused on the timely execution of startup activities for verekitug’s Phase 3 trials in severe asthma and CRSwNP. Preparations for the planned initiation of these trials in the first quarter of 2027 are well underway, with key clinical, regulatory, and manufacturing milestones now having been achieved.”
Rand Sutherland, MD, Chief Executive Officer of Upstream Bio
“As we look ahead, we remain focused on advancing verekitug in diseases with significant remaining unmet medical need, where we believe its compelling efficacy profile and convenient quarterly at-home dosing have the opportunity to meaningfully redefine treatment expectations and establish a new standard of care.”
Rand Sutherland, MD, Chief Executive Officer of Upstream Bio